Remove 2029 Remove Chemotherapy Remove Drug Development
article thumbnail

Antibody-drug conjugates: paving the future of oncology clinical development

European Pharmaceutical Review

Antibody-drug conjugates (ADCs), such as datopotamab deruxtecan (Dato-DXd) and trastuzumab deruxtecan, have demonstrated compelling evidence of efficacy in oncology across numerous diseases in recent months.